Literature DB >> 26137350

Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition.

Daria M Zajac1, Sarah R Sikkema1, Ranjith Chandrasena1.   

Abstract

Entities:  

Year:  2015        PMID： 26137350      PMCID： PMC4468877          DOI： 10.4088/PCC.14l01695

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  14 in total

1.  Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia.

Authors:  Sebastian Walther; Brigitte Schüpbach; Erich Seifritz; Philipp Homan; Werner Strik
Journal:  J Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.153

2.  Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease.

Authors:  L Volicer; M Stelly; J Morris; J McLaughlin; B J Volicer
Journal:  Int J Geriatr Psychiatry       Date:  1997-09       Impact factor: 3.485

3.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

Authors:  Lon S Schneider; Karen Dagerman; Philip S Insel
Journal:  Am J Geriatr Psychiatry       Date:  2006-03       Impact factor: 4.105

Review 4.  Pharmacological actions and therapeutic uses of cannabis and cannabinoids.

Authors:  R N Kumar; W A Chambers; R G Pertwee
Journal:  Anaesthesia       Date:  2001-11       Impact factor: 6.955

Review 5.  Pharmacokinetics of cannabinoids.

Authors:  Iain J McGilveray
Journal:  Pain Res Manag       Date:  2005       Impact factor: 3.037

6.  Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

Authors:  Constantine G Lyketsos; Oscar Lopez; Beverly Jones; Annette L Fitzpatrick; John Breitner; Steven DeKosky
Journal:  JAMA       Date:  2002-09-25       Impact factor: 56.272

Review 7.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

8.  Predictors of institutionalisation in people with dementia.

Authors:  S Banerjee; J Murray; B Foley; L Atkins; J Schneider; A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

9.  Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.

Authors:  Sebastian Walther; Richard Mahlberg; Uta Eichmann; Dieter Kunz
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

10.  The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation.

Authors:  Michael J Passmore
Journal:  Int J Geriatr Psychiatry       Date:  2008-01       Impact factor: 3.485
View more
  3 in total

Review 1.  Cannabinoids for the treatment of dementia.

Authors:  Dina Bosnjak Kuharic; Domagoj Markovic; Tonci Brkovic; Milka Jeric Kegalj; Zana Rubic; Ana Vuica Vukasovic; Ana Jeroncic; Livia Puljak
Journal:  Cochrane Database Syst Rev       Date:  2021-09-17

Review 2.  Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review.

Authors:  Jodie Belinda Hillen; Natalie Soulsby; Chris Alderman; Gillian E Caughey
Journal:  Ther Adv Drug Saf       Date:  2019-05-15

3.  Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review.

Authors:  Florindo Stella; Leandro C Lane Valiengo; Vanessa J R de Paula; Carlos Augusto de Mendonça Lima; Orestes V Forlenza
Journal:  Trends Psychiatry Psychother       Date:  2021-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.